RARE vs ALNY: Ultragenyx vs Alnylam Stock Comparison: AI Score, Valuation, Performance and Upside
Ultragenyx is a commercial rare disease company pivoting toward gene therapy with a diversified approved product portfolio, while Alnylam is the world leader in RNA interference therapeutics with multiple approved drugs and a large ATTR amyloidosis market opportunity. Alnylam is the more advanced and validated rare disease platform; Ultragenyx has gene therapy optionality.
RARE vs ALNY is a gene therapy-pivoting rare disease biotech versus the world's leading RNA interference medicines company — Alnylam has more validated commercial revenue and a larger market opportunity; Ultragenyx offers gene therapy upside at an earlier stage of execution.
ALNY holds the edge across 4 of 5 key metrics in this comparison. ALNY leads on both 1-year return (-50.23%) and forward P/E quality (19.94x vs 39.86x for RARE), a relatively favorable combination of momentum and valuation. ALNY leads on both revenue growth (66.90%) and operating margin (17.93%), suggesting a stronger fundamental setup on both dimensions. Analyst consensus implies meaningfully more upside for RARE (+108.30%) than for ALNY (+49.33%).
Human Wall Street analysts' price targets, typically implying a ~12-month view — a separate signal from this site's own AI Prediction Signal further down the page, which is a 5-/30-day machine-learning forecast based on price history alone.
- want rare disease exposure with gene therapy pipeline as additional upside
- value Crysvita and Dojolvi as commercial products that fund R&D without full burn
- believe gene therapy will become a standard treatment modality for metabolic rare diseases
- are comfortable with extended profitability timeline as gene therapy pipeline advances
- prefer the world leader in validated RNA interference medicines with multiple approved drugs
- value the ATTR amyloidosis market as a large, growing, underpenetrated revenue opportunity
- want the more commercially advanced rare disease and cardiovascular RNAi platform
- are comfortable with competitive ATTR landscape and payer scrutiny on high-cost drugs
| Metric | RARE | ALNY |
|---|---|---|
| AI scorei | 24.7 | 61.1 |
| AI ranki | #2755 | #130 |
| Latest closei | $15.17 | $234.03 |
| 1M returni | +16.07% | -1.78% |
| 3M returni | -49.80% | -17.35% |
| 6M returni | -38.13% | -26.90% |
| 1Y returni | -54.62% | -50.23% |
How much would $10,000 be worth today if invested at the start of each period, with all dividends reinvested?
| Period | RARE | ALNY |
|---|---|---|
| 1Y ago | $4.47K (-55.3%) started 2025-10-16 | $4.86K (-51.4%) started 2025-10-16 |
| 5Y ago | $1.94K (-80.6%) started 2021-10-18 | $11.48K (+14.8%) started 2021-10-18 |
| 10Y ago | $2.5K (-75.0%) started 2016-10-17 | $63.98K (+539.8%) started 2016-10-17 |
Hypothetical — past performance does not guarantee future results.
| Metric | RARE | ALNY |
|---|---|---|
| Market capi | $2.62B | $33.28B |
| Trailing P/Ei | N/A | 43.32 |
| Forward P/Ei | 39.86 | 19.94 |
| Price/Salesi | N/A | N/A |
| EV/Revenuei | 4.92 | 6.86 |
| Analyst targeti | $55.26 | $371.35 |
| Target upsidei | +108.30% | +49.33% |
| Metric | RARE | ALNY |
|---|---|---|
| Revenue growthi | 28.10% | 66.90% |
| Earnings growthi | N/A | N/A |
| EPS growthi | N/A | N/A |
| FCF margini | -25.08% | +5.65% |
| Operating margini | -35.05% | 17.93% |
| Profit margini | -81.73% | 16.13% |
| ROIC proxyi | N/A | 96.56% |
| Return on equityi | N/A | 96.56% |
| Dividend yieldi | N/A | N/A |
| Payout ratioi | N/A | 0.00% |
| Dividend growth streaki | N/A | N/A |
| Betai | 0.31 | 0.30 |
| Debt/equityi | N/A | 220.62 |
| Current ratioi | 1.73 | 3.06 |
| Quick ratioi | 1.41 | 2.79 |
Over the past year, RARE and ALNY have moved barely in the same direction (correlation of 0.11), based on daily returns.
Lower drawdown and smaller single-period drops generally indicate a smoother ride, though they do not guarantee lower future risk.
| Period | Metric | RARE | ALNY |
|---|---|---|---|
| 1Y | Growthi | -55.34% | -51.35% |
| CAGRi | -55.40% | -51.41% | |
| Volatilityi | 81.46% | 48.23% | |
| Sharpe ratioi | -0.54 | -1.33 | |
| Sortino ratioi | -0.64 | -1.58 | |
| Max drawdowni | 64.75% | 58.17% | |
| Current drawdowni | 58.48% | 52.36% | |
| Avg drawdowni | 30.09% | 33.96% | |
| Ulcer Indexi | 34.65% | 37.05% | |
| Max daily dropi | 44.03% | 28.31% | |
| Max wkly dropi | 45.72% | 24.38% | |
| 5Y | Growthi | -80.56% | +14.78% |
| CAGRi | -27.96% | +2.80% | |
| Volatilityi | 58.21% | 50.89% | |
| Sharpe ratioi | -0.32 | 0.21 | |
| Sortino ratioi | -0.41 | 0.33 | |
| Max drawdowni | 85.34% | 58.17% | |
| Current drawdowni | 82.73% | 52.36% | |
| Avg drawdowni | 50.86% | 20.85% | |
| Ulcer Indexi | 53.79% | 25.17% | |
| Max daily dropi | 44.03% | 28.31% | |
| Max wkly dropi | 45.72% | 24.38% | |
| 10Y | Growthi | -75.03% | +539.78% |
| CAGRi | -12.96% | +20.40% | |
| Volatilityi | 56.91% | 52.00% | |
| Sharpe ratioi | -0.02 | 0.52 | |
| Sortino ratioi | -0.03 | 0.84 | |
| Max drawdowni | 92.74% | 58.17% | |
| Current drawdowni | 91.45% | 52.36% | |
| Avg drawdowni | 53.12% | 21.35% | |
| Ulcer Indexi | 59.17% | 26.28% | |
| Max daily dropi | 44.03% | 28.31% | |
| Max wkly dropi | 45.72% | 28.23% |
| Category | RARE | ALNY |
|---|---|---|
| Company | Ultragenyx Pharmaceutical Inc. | Alnylam Pharmaceuticals, Inc. |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
| Core business | Rare disease biopharmaceutical company with approved treatments including Crysvita (X-linked hypophosphatemia), Dojolvi (LC-FAOD), and Evkeeza (homozygous familial hypercholesterolemia). Ultragenyx's pipeline emphasizes gene therapy for rare metabolic disorders. | RNA interference (RNAi) therapeutics leader with multiple approved drugs: Onpattro, Givlaari, Oxlumo, Leqvio (co-commercialized with Novartis), and Amvuttra for ATTR amyloidosis. RNAi silences disease-causing genes by degrading mRNA before protein production. |
| Investor focus | Crysvita global revenue ramp, gene therapy clinical progress, pipeline acceleration, and path to profitability as commercial products scale. | Amvuttra and Leqvio revenue ramp, ATTR amyloidosis market penetration, royalties from Novartis Leqvio co-promotion, and pipeline advancement in cardiovascular disease. |
- Diversified commercial rare disease portfolio provides revenue while gene therapy pipeline advances
- Gene therapy expertise positions Ultragenyx in a next-generation treatment modality for rare genetic disorders
- Strong orphan drug designation history provides regulatory and commercial exclusivity advantages
- Alnylam has validated the RNAi platform with multiple approved drugs across rare diseases and cardiovascular conditions
- ATTR amyloidosis market for Amvuttra is large and growing — millions of undiagnosed patients represent significant upside
- Leqvio partnership with Novartis provides commercial muscle without full Alnylam marketing investment
- Rare disease drugs face reimbursement challenges from payers who scrutinize high-cost treatments
- Gene therapy programs are earlier-stage with uncertain clinical and regulatory timelines
- Profitability timeline remains extended as R&D investment for gene therapy is significant
- Competitive landscape for ATTR amyloidosis includes Pfizer (tafamidis) and other gene silencing approaches
- RNAi drug pricing is subject to payer scrutiny in rare disease and now cardiovascular populations
- Pipeline beyond ATTR and cardiovascular requires further clinical validation to sustain premium valuation
Compare more than two at a time
This page is a fixed writeup on RARE and ALNY. Our comparison engine is the interactive version: load up to five tickers, switch timeframes, and get the correlation, drawdown, and overlap analysis that a static page can't show.
Add three more names beside RARE and ALNY, mixing stocks and ETFs in the same table — useful when the real question is which of a whole peer group to own.
AI score, forward P/E, analyst target upside, operating margin, and revenue growth are scored head-to-head, with a running tally of which ticker leads on how many metrics.
Volatility, Sharpe and Sortino ratios, maximum, current, and average drawdown, Ulcer Index, and worst single-day and single-week drops across every timeframe.
Pairwise daily-return correlation for every combination, so you can see whether two holdings actually diversify each other or just move together.
A scatter plot of forward P/E against return on equity, plus drawdown and 30-day rolling volatility charts, to separate what is cheap from what is merely beaten down.
For ETFs, a top-holdings comparison that exposes hidden overlap between funds. Every comparison exports to CSV for your own spreadsheet work.
Two comparisons a week are free without an account. A 14-day trial removes the limit and adds AI price forecasts, stock rankings, saved watchlists, and the intrinsic value calculator — no credit card required.
Want deeper AI forecasts?
This comparison page is public and free forever. Subscribers can unlock saved watchlists, full AI rankings, detailed forecasts, and interactive analysis tools.
Full valuation workup with AI Score, Monte Carlo forecast, and bull/bear case — free preview, premium data from $3.99.